ロード中...
Ranolazine-induced Elevation of Creatinine Kinase in the Absence of Statin Usage
Ranolazine received Food and Drug Administration (FDA) approval in 2006 for the treatment of chronic angina. Ranolazine has previously been linked to the development of statin-induced myopathy, because it also inhibits CYP3A4, which increases serum statin levels. In the absence of concomitant statin...
保存先:
| 出版年: | Cureus |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Cureus
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6101463/ https://ncbi.nlm.nih.gov/pubmed/30131925 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.2832 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|